Should I Buy ELDN? ELDN 2026 Analysis

Should You Buy Eledon Pharmaceuticals Inc (ELDN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

2.190

1 Day change

11.17%

52 Week Range

4.960

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient investor: there’s no near-term catalyst (no news/events) and the short-horizon pattern/forecast skew is slightly negative.
Price is sitting just below the pivot (2.194) with nearby support at ~2.091; risk/reward improves closer to support rather than at 2.175.
Sentiment signals are mixed: hedge funds have been accumulating, but options activity is thin despite an extremely call-heavy open interest.
Intellectia Proprietary Trading Signals
- AI Stock Picker: No signal on given stock today.
- SwingMax: No signal on given stock today.

Technical Analysis

Trend/structure: moving averages are converging → no strong established trend; current action is more range-bound than trending.
MACD: histogram slightly above 0 (0.00334) but positively contracting → bullish momentum is fading rather than building.
RSI(6): 51.7 (neutral) → neither oversold nor overbought; no momentum edge for an immediate buy.
Key levels: Pivot 2.194 (price 2.175 is below it = mild bearish bias). Support S1 2.091 then S2 2.027; Resistance R1 2.297 then R2 2.361.
Short-horizon statistical read (similar candlestick patterns): modest downside bias over 1d/1w/1m (expected -0.61% / -1.23% / -0.37%).

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning: Open interest put/call ratio at 0.09 is extremely call-skewed (bullish positioning), but it can also reflect speculative call concentration.
Activity/liquidity: Today’s total options volume is very low (11 calls, 0 puts) → the signal quality from volume is weak.
Volatility: 30D IV is very high (~224%), but IV percentile ~27.9 / IV rank ~20 suggests IV is not at the top of its own historical range.
Interpretation: Sentiment/positioning leans bullish, but thin volume and very high absolute IV keep option-derived conviction modest.

Technical Summary

Sell

Buy

Positive Catalysts

- Hedge fund activity: “Hedge Funds are Buying” with buying amount up ~138.83% QoQ (supportive institutional flow).
- Analyst stance remains constructive: Guggenheim maintains a Buy rating (despite trimming target).
- If price holds above ~2.09 and reclaims pivot ~2.19, a technical bounce toward ~2.30 becomes more plausible.

Neutral/Negative Catalysts

- No news in the last week → lack of near-term event-driven catalyst for a quick move (important for an impatient buyer).
- Recent dilution overhang referenced by analyst (fund raising) can cap rallies and pressure shares.
- Options market is extremely call-skewed, but with minimal volume; a crowded call positioning can be fragile if price weakens.
- Market backdrop slightly risk-off (S&P 500 -0.31% today), which can weigh on small-cap biotech.

Financial Performance

Latest reported quarter: 2025/Q3.
Revenue: 0 (no meaningful revenue base).
Profitability: Net income -$17.459M (slightly worse YoY), EPS -0.23 (down ~32.35% YoY) → losses per share widened.
Takeaway: fundamentals remain development-stage/earnings-negative; the trade case is primarily sentiment/catalyst-driven rather than operating growth-driven.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

[2025-11-18] Guggenheim: Maintains Buy; price target cut to $8 from $9 due to Q3 updates and incorporating dilution from financing.
Wall Street pros: Large implied upside vs $2.175 if execution/catalysts hit; supportive institutional buying trend.
Wall Street cons: Dilution risk and ongoing losses with no revenue base; without a clear upcoming catalyst, timing is less favorable for an impatient entry.

5 Analyst Rating

Wall Street analysts forecast ELDN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELDN is 7.75 USD with a low forecast of 4 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 1.970

Low

Averages

7.75

High

Current: 1.970

Low

Averages

7.75

High

Guggenheim

Buy

maintain

$9 -> $8

AI Analysis

2025-11-18

Reason

Guggenheim

Price Target

$9 -> $8

AI Analysis

2025-11-18

maintain

Buy

Reason

Guggenheim lowered the firm's price target on Eledon Pharmaceuticals to $8 from $9 and keeps a Buy rating on the shares following the Q3 report last week. In addition to "routine incrementally positive adjustments," the firm is also incorporating the dilution from the recent fund raising, the analyst tells investors.

Craig-Hallum

NULL -> Buy

initiated

$12

2025-07-25

Reason

Craig-Hallum

Price Target

$12

2025-07-25

initiated

NULL -> Buy

Reason

Craig-Hallum initiated coverage of Eledon Pharmaceuticals with a Buy rating and $12 price target.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ELDN

Unlock Now

ELDN Should I Buy

ELDN Should I Buy

Should You Buy Eledon Pharmaceuticals Inc (ELDN) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch